Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study.

Indian journal of cancer - 1 Jan 2000

Kumar R, Dubashi B, Kayal S, Lazzar S C, Barathi D, Kumar V

Abstract excerpt

BACKGROUND: Maintenance treatment of patients with advanced nonsmall cell lung cancer (NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing research. The aim of this study was to investigate the efficacy, safety, and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor, i.e., gefitinib in the maintenance setting irrespective of EGFR status....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug-Related Side Effects and Adverse Reactions

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Neoplasm Metastasis

Share to Quinazolines

Source

Identifiers

PMID: 29199688
DOI: 10.4103/ijc.IJC_46_17

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study.PMID 29199688Read ↗

Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.Semantic proximity Read ↗

Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.Semantic proximity Read ↗

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.Semantic proximity Read ↗

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.Semantic proximity Read ↗

Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.Semantic proximity Read ↗

Switch Maintenance Tyrosine Kinase Inhibitors in EGFR Mutation Positive Metastatic Non-squamous NSCLC: Experience from the real world.Semantic proximity Read ↗

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.Semantic proximity Read ↗

Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.Semantic proximity Read ↗

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations.Semantic proximity Read ↗

Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.Semantic proximity Read ↗

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.